Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Trevena Inc (TRVN) USD0.001

Sell:$0.93 Buy:$0.93 Change: $0.001 (0.11%)
NASDAQ:0.91%
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Sell:$0.93
Buy:$0.93
Change: $0.001 (0.11%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Sell:$0.93
Buy:$0.93
Change: $0.001 (0.11%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Contact details

Address:
955 Chesterbrook Blvd Ste 110
CHESTERBROOK
19087-5627
United States
Telephone:
+1 (610) 3548840
Website:
www.trevena.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TRVN
ISIN:
US89532E1091
Market cap:
$86.09 million
Shares in issue:
92.57 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Leon Moulder
    Independent Chairman of the Board
  • Carrie Bourdow
    President, Chief Executive Officer, Director
  • Barry Shin
    Chief Financial Officer
  • John Limongelli
    Chief Administrative Officer, Senior Vice President, General Counsel, Secretary
  • Mark Demitrack
    Senior Vice President and Chief Medical Officer
  • Yacoub Habib
    Senior Vice President - Business Development and Corporate Planning
  • Robert Yoder
    Senior Vice President and Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.